463
Views
9
CrossRef citations to date
0
Altmetric
Dermatology

Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use

, , &
Pages 1387-1395 | Received 19 Nov 2018, Accepted 20 Feb 2019, Published online: 28 Mar 2019

References

  • Bernstein JA, Lang DM, Khan DA. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133:1270–1277.
  • Kaplan AP. Angioedema. World Allergy Organ J. 2008;1:103–113.
  • Beck LA, Bernstein JA, Maurer M. A review of international recommendations for the diagnosis and management of chronic urticaria. Acta Derm Venereol. 2017;97:149–158.
  • Boubouka CD, Charissi C, Kouimintzis D, et al. Treatment of autoimmune urticaria with low-dose cyclosporin A: a one-year follow-up. Acta Derm Venereol. 2011;91:50–54.
  • Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66:317–330.
  • United States Census Bureau. Census Bureau Projects U.S. Population and World Populations on New Year’s Day [Internet]. 2016 [cited 2018 Oct 23]. Available from: http://www.census.gov/newsroom/press-releases/2016/cb16-tps158.html
  • O’Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136:197–201.
  • Mendelson MH, Bernstein JA, Gabriel S, et al. Patient-reported impact of chronic urticaria compared with psoriasis in the United States. J Dermatolog Treat. 2017;28:229–236.
  • Ben-Shoshan M, Blinderman I, Raz A. Psychosocial factors and chronic spontaneous urticaria: a systematic review. Allergy. 2013;68:131–141.
  • Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393–1414.
  • Genentech Inc. Xolair prescribing information [Internet]. 2018 [cited 2018 Oct 23]. Available from: https://www.gene.com/download/pdf/xolair_prescribing.pdf
  • Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–935.
  • Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67–75.
  • Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: disease-specific programmes – a means to understand. Curr Med Res Opin. 2008;24:3063–3072.
  • US Department of Health and Human Services. Summary of the HIPAA Privacy Rule [Internet]. 2003 [cited 2018 Oct 23]. Available from: http://www.hhs.gov/sites/default/files/privacysummary.pdf
  • Health Information Technology. Health Information Technology Act [Internet]. 2009 [cited 2018 Oct 23]. Available from: https://www.healthit.gov/sites/default/files/hitech_act_excerpt_from_arra_with_index.pdf
  • Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005;60:1073–1078.
  • Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 1968;70:213–220.
  • Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174.
  • Vietri J, Turner SJ, Tian H, et al. Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. Ann Allergy Asthma Immunol. 2015;115:306–311.
  • Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72:2005–2016.
  • Barton JL, Imboden J, Graf J, et al. Patient–physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010;62:857–864.
  • Ryan C, Menter A. Discordance between physician assessment of psoriasis and patient self-assessment: the importance of itch. Br J Dermatol. 2016;175:19–20.
  • Smolen JS, Strand V, Koenig AS, et al. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res Ther. 2016;18:114.
  • Gupta MA, Gupta AK. Sleep–wake disorders and dermatology. Clin Dermatol. 2013;31:118–126.
  • Gimenéz-Arnau AM, Spector S, Antonova E, et al. Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies. Clin Transl Allergy. 2016;6:32.
  • DeLong LK, Culler SD, Saini SS, et al. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 2008;144:35–39.
  • Broder MS, Raimundo K, Antonova E, et al. Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticaria. Am J Clin Dermatol. 2015;16:313–321.
  • Al-Ahmad M, Alowayesh MS, Carroll NV. Economic burden of refractory chronic spontaneous urticaria on Kuwait’s health system. Clinicoecon Outcomes Res. 2016;8:163–169.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.